All content on this website is provided for educational and research purposes only. It does not constitute medical advice or treatment. This article discusses biological mechanisms also observed in laboratory and preclinical research models, so no clinical efficacy or safety for human use is implied. The substances discussed, which are not registered medicines, are not intended for use in humans or animals.

HGH Fragment 176-191

HGH Fragment 176-191 is a synthetic peptide derived from a specific segment of human growth hormone (hGH). It has been studied for its potential influence on fat metabolism and energy balance.

HGH Fragment 176-191 corresponds to amino acids 176-191 of the full Human growth hormone molecule. This region of the hormone has been identified in research as being associated with pathways involved in lipolysis (fat breakdown).

Unlike full growth hormone therapy, this peptide was designed to isolate metabolic effects related to fat metabolism while minimizing the broader endocrine effects associated with growth hormone signaling.

How HGH Fragment 176-191 works

HGH Fragment 176-191 is believed to influence metabolic pathways associated with lipid metabolism in adipose tissue. Experimental research suggests that the peptide may:

  • stimulate lipolysis, the breakdown of stored fat

  • inhibit lipogenesis, the formation of new fat cells

  • influence signaling pathways involved in energy balance and metabolism

Importantly, studies suggest that this peptide does not significantly activate the growth hormone receptor, meaning it does not produce the full range of hormonal effects associated with growth hormone therapy.

Because of this selective mechanism, HGH Fragment 176-191 has been investigated in research related to metabolic regulation and obesity.

Clinical trials and evidence

Research involving HGH Fragment 176-191 has included laboratory experiments and clinical studies investigating its effects on body fat and metabolic parameters. Some studies have examined:

  • the role of growth hormone fragments in fat metabolism

  • experimental approaches to targeting adipose tissue metabolism

  • metabolic pathways related to lipid regulation

While certain experimental findings suggested possible effects on fat metabolism, clinical evidence has been limited and mixed, and the peptide did not progress to widespread pharmaceutical approval as a treatment for obesity.

As a result, most available data come from preclinical research and early clinical investigations.

Possible side effects of HGH Fragment 176-191:

Because HGH Fragment 176–191 has primarily been studied in experimental settings, its complete safety profile in humans is not fully established. Reported or possible side effects may include:

  • headache

  • mild gastrointestinal discomfort

  • fatigue

  • injection site reactions

As with other investigational peptides affecting metabolic pathways, the long-term safety of this compound requires further clinical research.

Materiały referencyjne:

– Metabolic studies of a synthetic lipolytic domain (176–191) of human growth hormone, Ng et al., 2000 – Hormone Research, https://www.nejm.org/doi/pdf/10.1056/nejmoa2206038

– The Effects of Human GH and Its Lipolytic Fragment (AOD9604) on Lipid Metabolism…, Heffernan et al., 2001 – Endocrinology, https://academic.oup.com/endo/article-abstract/142/12/5182/2988749

– Increase of fat oxidation and weight loss in obese mice caused by a modified C‑terminal fragment (176‑191), Heffernan et al., 2001 – Int. J. Obesity, https://www.ahajournals.org/doi/pdf/10.1161/JAHA.122.026297

HGH Fragment 176–191 is considered an experimental peptide studied primarily in metabolic and endocrine research and is not approved as a prescription medication by major regulatory authorities. Scientific research involving such compounds should be conducted with appropriate safety precautions and in accordance with applicable laws and regulations in the relevant country.

The purpose of this website is to provide clear, evidence-based information about biologically active compounds often discussed in research, metabolic health, and biohacking communities. The information presented here is educational and should not be considered medical advice.

HGH Fragment 176-191
Action: Fat metabolism regulation | Category: growth hormone fragment
Experimental dosage: 250–500 mcg | Frequency: 1–2× a day | Timing: morning / pre‑workout | Cycle on: 8–12 weeks — Route: subcutaneous (SC). Stop rules: hold and seek medical advice if moderate/severe adverse effects occur (e.g., escalating nausea/vomiting, dizziness, palpitations, significant blood pressure changes, severe injection‑site reactions, allergic symptoms) or if there is no clear ‘return‑to‑baseline’ window between doses. | Cycle off: 4 weeks
Effectiveness: ■■■▢▢ | Safety: ■■■▢▢

Related peptides

Peptides from the same functional group:5-Amino-1MQ (5-Amino-1-methylquinolin-1-ium Iodide), AICAR, L-Carnitine, Livagen

Our peptides database

5-Amino-1MQ | AICAR peptide | AOD9604 peptide | Arg-BPC-157 peptide | BPC-157 peptide | CagriSema | Cerebrolysin peptide | CJC-1295 NO DAC peptide | CJC-1295 with DAC peptide | Cortagen peptide | Dihexa peptide | DSIP peptide (Delta Sleep-Inducing Peptide) | Dulaglutide peptide | Epithalon peptide | Exenatide peptide | Follistatin 315 peptide | Follistatin 344 peptide | FOXO4-DRI peptide | GHK-Cu peptide | GHRP-2 peptide | GHRP-6 peptide | Hexarelin peptide | HGH Fragment 176-191 | Humanin peptide | IGF-1 LR3 peptide | Ipamorelin CJC-1295 NO DAC | Ipamorelin peptide | Kisspeptin peptide | KPV peptide | L-Carnitine | Liraglutide peptide | Livagen peptide | LL-37 peptide | Matrixyl peptide | Mazdutide peptide | Melanotan II peptide | Melanotan peptide | MGF peptide (Mechano Growth Factor peptide) | MOD GRF 1-29 | MOTS-C peptide | NAD+ coenzime (Nicotinamide Adenine Dinucleotide) | Oxytocin peptide | P21 peptide | PEG-MGF peptide | Pinealon peptide | PT-141 peptide (Bremelanotide) | PTD-DBM peptide | Retatrutide | Selank peptide | Semaglutide | Semax peptide | Sermorelin peptide | SHLP-2 peptide | SHLP-6 peptide | Somatropin peptide | SS-31 peptide (Elamipretide) | TB-500 peptide | Tesamorelin peptide | Thymosin Alpha 1 peptide | Thymosin beta 4 peptide | Thymosin β10 peptide | Thymulin peptide | Tirzepatide | Vilon peptide
Tagged